Behnam B Badie MD F.A.C.S.
Brain & Spinal Tumor, Pituitary Surgery, Skull Base
Chief, Division of Neurosurgery | Director, Brain Tumor Program | Vice Chair & Professor, Department of Surgery at City of Hope
Join to View Full Profile
Division of Neurosurgery1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-471-7344
Dr. Badie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified neurosurgeon and current vice chair & professor, Department of Surgery and chief, Division of Neurosurgery at City of Hope in Duarte, California. I am also the director of the Brain Tumor Program at City of Hope.
I am an expert in the field of surgical neuro-oncology, and our Brain Tumor Program and Division of Neurosurgery is leading groundbreaking research into nanotechnology as a tool for delivering cancer-fighting drugs directly into tumors, in a minimally invasive manner.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurological Surgery, 1990 - 1996- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Transitional Year, 1989 - 1990
David Geffen School of Medicine at UCLAClass of 1989
Certifications & Licensure
CA State Medical License 1991 - 2026
WI State Medical License 1996 - 2007
American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Start of enrollment: 2010 May 01
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Start of enrollment: 2015 May 18
- Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Start of enrollment: 2018 Aug 14
- Join now to see all
Publications & Presentations
PubMed
- Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety.Michael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, M Suzette Blanchard, Julie R Ostberg
Cell Reports. Medicine. 2025-08-19 - Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.Karl J Habashy, Timothy W Synold, Ye Feng, Cristal Gomez, Christina Amidei
Clinical Cancer Research. 2025-08-14 - Towards a Steerable Neurosurgical Robot for Debulking of Brain Mass Lesions.Sarvesh Saini, Saeed Rezaeian, Arshia Akbari, Behnam Badie, Jun Sheng
IEEE Robotics and Automation Letters. 2025-05-01
Press Mentions
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022March 9th, 2022- Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022March 9th, 2022
- City of Hope Physicians and Scientists Present New Immunotherapy Research at ASCO Virtual ConferenceJune 3rd, 2021
- Join now to see all
Grant Support
- Novel Cell Delivery Method for Brain Tumor TherapyNational Cancer Institute (NCI)2014–Present
- Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma TherapyNINDS2013–Present
- Role Of Receptor For Advanced Glycation END Product (RAGE) Pathway In Brain TumorNational Cancer Institute2011
- Application Of Carbon Nanotubes For Macrophage Activation In Brain Tumor ModelsNational Cancer Institute2009–2010
Professional Memberships
- Member
- Fellow
Other Languages
- Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
